skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Selective p38α mitogen-activated protein kinase inhibitor attenuates lung inflammation and fibrosis in IL-13 transgenic mouse model of asthma

Original Research

(2801) Views  (737) Full article downloads

Authors: Jing Ying Ma, Satyanarayana Medicherla, Irene Kerr, Ruban Mangadu, Andrew A Protter, Linda S Higgins

Published Date November 2008 Volume 2008:1 Pages 31 - 44
DOI: http://dx.doi.org/10.2147/JAA.S4199

Jing Ying Ma1, Satyanarayana Medicherla1, Irene Kerr, Ruban Mangadu, Andrew A Protter, Linda S Higgins

1Scios Inc, Fremont, CA, USA 1Jing Ying Ma and Satyanarayana Medicherla contributed equally to this work

Abstract: p38 Mitogen-activated protein kinase (MAPK) plays a critical role in the activation of inflammatory cells. We investigated the anti-inflammatory effects of a p38α-selective MAPK inhibitor (SD-282) in a mouse transgenic (CC10:IL-13) asthma model. The CC-10-driven over-expression of IL-13 in the mouse lung/airway has been shown to result in a remarkable phenotype recatitulating many features of asthma and characterized by eosinophilic and mononuclear inflammation, with airway epithelial cell hypertrophy, mucus cell metaplasia, the hyperproduction of neutral and acidic mucus, the deposition of Charcot–Leyden-like crystal, and airway sub-epitheilial fibrosis. Here we show how activated p38 MAPK can be observed in the lungs at the onset of asthma ie, around 8 weeks of age in both female and male mice. We also show that administration of a p38α MAPK selective inhibitor, SD-282 at 30 or 90 mg/kg, twice a day for a period of four weeks beginning at the onset of asthma, significantly reduced the inflammation (p < 0.001); hyperplasia of airway epithelium (p < 0.05); goblet cell metaplasia and mucus hypersecretion (p < 0.001) and reduced lung remodeling and fibrosis (p < 0.01), alleviating the severity of lung damage as measured by a composite score (p < 0.05). Furthermore, SD-282 significantly reduced activated p38 MAPK in the lymphocytes and epithelial cells (p < 0.001). Simultaneously, identical studies were conducted with an anti-fibrotic TGFβR1 kinase inhibitor (SD-208) which demonstrated anti-fibrotic but not anti-inflammatory properties. These findings suggest that the p38α-selective MAPK inhibitor may have dual therapeutic potential in attenuating both the inflammatory component and the fibrotic component of asthma and other Th2-polarized inflammatory lung diseases.

Keywords: inflammation, asthma, fibrosis, p38α-selective MAPK inhibitor, SD-282, phosphorylated p38 MAPK, TGFβ inhibitor, SD-208, phosphorylated SMAD2/3








Readers of this article also read:

Introduction of Asthma APGAR tools improve asthma management in primary care practices
Metabolism of ciclesonide in the upper and lower airways: review of available data
The effect of cotton-based collection methods on eosinophil cationic protein (ECP) concentrations detected in saliva
Intranasal ciclesonide for allergic rhinitis
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Treatment of moderate to severe asthma: patient perspectives on combination inhaler therapy and implications for adherence
Perception of risk and benefit in patient-centered communication and care
The relationship between deliberate self-harm behavior, body dissatisfaction, and suicide in adolescents: current concepts
Zinc oxide nanoparticles as selective killers of proliferating cells
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy